Merlyna Savitri and Siprianus Ugroseno Yudho Bintoro and Made Putra Sedana and Muhammad Noor Muhammad and Pradana Zaky Romadhon and Putu Niken Ayu Amrita and Andi Yasmin Wijaya and Winona May Hendrata and Ami Ashariati Prayoga (2020) Circulating Plasma miRNA-21 as a Superior Biomarker Compared to CA 15-3: Assessment in Healthy Age Matched Subjects and Different Stage of Breast Cancer Patients. The Indonesian Biomedical Journal, 12 (2). pp. 185-188. ISSN 2085-3297

	Text (Artikel) 4. Circulating Plasma miRNA-21 as a Superior Biomarker Compared to CA 15.pdf Download (1MB)
	Text (Peer Review) Circulating Plasma.pdf Download (1MB)
	Text (Similarity) Circulating Plasma miRNA-21 as a Superior Biomarker Compared to CA 15-3_ Assessment in Healthy Age Matched Subjects and Different Stage of Breast Cancer Patients.pdf Download (2MB)

Abstract

BACKGROUND: Carbohydrate antigens 15-3 (CA 15-3) is a conventional tumor marker in breast cancer, with low sensitivity and specificity. MicroRNA (miRNA)-21 showed its stability in circulation and could serve as powerful biomarker. The aim of this study was to evaluate miRNA-21 as breast cancer biomarker compared to CA 15-3 in Indonesian population. METHODS: Circulating plasma miRNA-21 expression was measured using qRT-PCR in 49 patients at various stages of breast cancer and 16 healthy controls. The relative expression value of miRNA-21 was calculated using 2-ΔΔCt. Meanwhile, CA 15-3 was quantified using electrochemiluminescence immunoassay (ECLIA) methods. The results of miRNA-21 and CA 15-3 plasma circulating expression were compared with controls at each stage and between stages of breast cancer. RESULTS: CA 15-3 median level in breast cancer group was 1.60 times higher compared to control group (p=0.019), 21.00 m/mL and 13.05 m/mL, respectively. Median miRNA-21 expression in breast cancer group was elevated 4.92 folds compared to control group (p=0.001), 4.43 and 0.90, respectively. There was no significant difference of CA 15-3 level between controls and all stages of breast cancer group. CA 15-3 cut-off value was 15.05 m/mL (p=0.016) with 59.2% sensitivity and 62.5% specificity. Meanwhile, there was a significant difference of miRNA-21 expression between controls and most stages of breast cancer group. Circulating miRNA-21 expression cut-off value was 2.07 (p=0.000) with 91.8% sensitivity and 87.5% specificity. CONCLUSION: Circulating miRNA-21 expression and CA 15-3 levels were significantly increased in breast cancer group compared to control group. The miRNA-21 expression increased consistently with breast cancer stage progression. miRNA-21 could serve as superior biomarker compared to CA 15-3.

Actions (login required)

View Item